Conclusão

As hemorroidas são uma condição clínica com sintomas que incluem retorragia, prolapso e comichão. Devido a outras condições poderem levar a sintomas idênticos, um exame físico direcionado, incluindo anuscopia e protosigmoidoscopia, deve de ser realizado. O tratamento depende da extensão da doença hemorroidária. As hemorroidas de grau I podem ser tratadas apenas com o tratamento conservador ou com uma das várias técnicas instrumentais. As hemorroidas de grau II e as de grau III relativamente pequenas são tratadas através do tratamento instrumental. A cirurgia é, geralmente, reservada para a minoria dos pacientes que têm grandes hemorroidas de grau III, hemorroidas de grau IV, hemorroidas externas trombosadas ou pacientes que foram submetidos a terapia menos agressiva com fracos resultados.

A recetividade dos panfletos por parte dos utentes da Farmácia Central foi bastante positiva, tendo sido necessário fazer a reposição frequente dos panfletos. Alguns pacientes mostraram-se muitos satisfeitos, referindo que a informação apresentada era importante e esclarecedora. Como profissional, fiquei extremamente satisfeita com o meu trabalho, pois é sempre gratificante sentirmo-nos úteis no exercício da nossa profissão, principalmente quando se trata de uma patologia tabu.

32

Bibliografia

1. Portaria n.º 137-A/2012, de 11 de Maio. Diário da República.

2. Decreto-Lei n.º 106-A/2010, de 1 de Outubro. Diário da República.

3. Sociedade Portuguesa de Hipertensão (2014). Tradução Portuguesa das Guidelines de 2013

da ESH/ESC para o tratamento da hipertensão arterial. Revista Portuguesa Hipertensão e

Risco Cardiovascular; 39:7-17.

4. Norma 002/2011, de 14 de Janeiro. Direção-Geral de Saúde.

5. Norma 019/2011, de 28 de Setembro. Direção-Geral de Saúde. Atualizada a 11 de Julho de

2013.

6. Robin G, Massart P, Letombe B (2007). La contraception des adolescents en France 2007.

Gynécologie Obstétrique & Fertilité; 35: 951-967.

7. Sociedade Portuguesa de Ginecologia (2011) Consenso sobre Contracepção 2011. In:

Reunião de Consenso Nacional sobre Contracepção; 15 de Novembro de 2011; Estoril, Portugal. Edições First News; 1-114.

8. Steyn PS, Goldstuck ND (2014). Contraceptive needs of the adolescent. Best Practice &

Research Clinical Obstretrics and Gynaecology; 1-11.

9. Orfão A, Leça A, Henriques A, Calado B, Branco J, Vicente L et al (2008). Saúde

Reprodutiva: Planeamento Familiar. Direção-Geral da Saúde, Lisboa.

10. Pitts S, Emans SJ (2014). Contraceptive counseling: Does it make a difference? Journal of

Adolescent Health; 54: 367-368

11. Yoost JL, Hertweck SP, Barnett SN (2014). The effect of an educational approach to

pregnancy prevention among high-risk early and late adolescents. Journal of Adolescent

Health; 1-6

12. Department of Reproductive Health and Research - Family and Community Health (2004).

Selected Practice Recommendations for Contraceptive Use. 2nd ed. World Health

Organization, Geneva

13. Trussell J (2004). Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, Nelson A,

Cates W, Guest F, Kowal D. Contraceptive Technology. 18th r.ed. Ardent Media, New York.

14. Archer JSM, Archer DF (2002). Oral contraceptive efficacy and antibiotic interaction: A

myth debunked. Journal of the American Academy of Dermatology; 46:917-23.

15. Varela, MG (2011). Contracepção hormonal. In: Oliveira CF, ed. Manual de Ginecologia -

volume II. Permanyer Portugal, Lisboa, 75-76.

16. Dragoman MV (2014). The combined oral contraceptive pill- recent developments, risks and

33

17. Dhont M, Verhaeghe V (2013). Hormonal anticonception anno 2013: a clinician’s view.

Facts, Views and visions in ObGyn; 5 (2):149-159.

18. Sherif K (1999). Benefits and risks of oral contraceptives. American Journal of Obstetrics &

Gynecology; 180 (6) (2): 343-348.

19. Reid R et al (2011). Oral contraceptives and the risk of venous thromboembolism: An

update. International Journal of Gynecology and Obstetrics; 112: 252-256.

20. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M (2013). Hormonal

contraceptives and venous thromboembolism: An epidemiological update. Best Practice &

Research Clinical Endocrinology & Metabolism; 27: 25-34.

21. Circular Informativa 268/CD/8.1.7. de 26/11/2013. Contracetivos Hormonais Combinados -

confirmação das recomendações do PRAC.

22. Reid R (2014). Oral hormonal contraception and venous thromboembolism (VTE).

Contraception; 89: 235-236.

23. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C (2009). Hormonal contraception and

risk of venous thromboembolism: national fallow-up study. BMJ; 339:b2890.

24. Brito MB, Nobre F, Vieira CS (2011). Contracepção hormonal e sistema cardiovascular.

Arquivos Brasileiros de Cardiologia; 96.4:81-89.

25. Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y

et al (2002). Risk of arterial thrombosis in relation to oral contraceptives (RATIO) Study:

Oral contraceptives and the risk of Ischemic stroke. Stroke; 33:1202-1208.

26. Plu-Bureau G, Hugon-Rodin J, Maitrot-Montelet L, Canonico M (2013). Hormonal

contraceptives and arterial disease: An epidemiological update. Best Practice & Research

Clinical Endocrinology & Metabolism; 27:35-45.

27. IARC (2012). Combined estrogen–progestogen contraceptives. IARC Monographs on the

Evaluation of Carcinogenic Risks to Humans; 100A: 283-317.

28. Silvera SAN, Miller AB, Rohan TE (2005). Oral contraceptive use and risk of breast cancer

among women with a family history of breast cancer: a prospective cohort study. Cancer

Causes and Control; 16:1059–1063.

29. Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, Stampfer MJ,

Willett WC (2010). Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiology, Biomarkers & Prevention; 19 (10):2496–2502.

30. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ (2007). Cancer risk

among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ; 1-8.

31. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P et al. (2010). Oral

contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis.

34

32. Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C et al. (2014). Timing of

oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast

Cancer Research and Treatment; 143:579–586.

33. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG et al. (2012). Oral

contraceptive formulation and risk of breast cancer. Contraception 85:342–350.

34. Vessey M, Yeates D (2007). Oral contraceptives and benign breast disease: an update of

findings in a large cohort study. Contraception; 76:418–424.

35. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR et al.

(2002). Oral contraceptives and the risk of breast cancer. The New England Journal of

Medicine; 346 (26): 2025-2032.

36. Gaffield ME, Culwell KR, Ravi A (2009). Oral contraceptives and family history of breast

cancer. Contraception; 80: 372-380.

37. Faber MT, Jensen A, Frederiksen K, Glud E, Høgdall E, Høgdall C et al. (2013). Oral

contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer. Cancer Causes Control; 24:2197–2206.

38. The ESHRE Capri Workshop Group (2005). Noncontraceptive health benefits of combined

oral contraception. Human Reproduction Update; 11 (5): 513–525.

39. Trémollieres F (2013). Impact of oral contraceptive on bone metabolism. Best Practice &

Research Clinical Endocrinology & Metabolism; 27:47–53.

40. Black A, Francoeur D, Rowe T, et al. (2004). Canadian Contraception Consensus. Journal of

Obstetrics and Gynaecology Canada; 26 (3):219-254.

41. Toh S, Mitchell AA, Anderka M, Jong-van den Berg LTW, Hernández-Díaz S (2011).

Antibiotics and oral contraceptive failure — a case-crossover study. Contraception; 83:418- 425.

42. Taylor J, Pemberton MN (2012). Antibiotics and oral contraceptives: New considerations for

dental practice. British Dental Journal; 212:481-483.

43. Sabers A (2008). Pharmacokinetic interactions between contraceptives and antiepileptic

drugs. Seizure; 17:141-144.

44. Rakinic J, Poola VP (2014). Hemorrhoids and fistulas: new solutions to old problems.

Currents Problems in Surgery; 51: 98-137.

45. Fernandes V, Camacho AG (2009). Doença hemorroidária. Revista Portuguesa de

Coloproctologia; 6 (2): 36-43.

46. Kann BR, Whitlow CB (2004). Hemorrhoids: diagnosis and management. Techniques in

Gastrointestinal Endoscopy; 6 (1): 6-11.

47. Ganz RA (2013).The evaluation and treatment of hemorrhoids: a guide for the

35

48. Kaidar-Person O, Person B, Wexner SD (2007). Hemorrhoidal disease: a comprehensive

review. Journal of the American College of Surgeons; 204 (1): 102-117.

49. De Deus JR, Pereira AD, da Silva PR (2010). Doença hemorroidária. Revista Portuguesa de

Coloproctologia; 7 (1): 28-31.

50. Gearhart SL (2004). Symptomatic hemorrhoids. Advances in Surgery; 50: 603-617.

51. Mounsey AL, Halladay J, Sadiq TS (2011). Hemorrhoids. American Family Physicians; 84

(2): 204-210.

52. Madoff RD, Fleshman JW (2004). American Gastroenterological Association Technical

Review on the Diagnosis and Treatment of Hemorrhoids. Gastroenterology; 126(5): 1463- 1473.

36